Bioma Probiotics Reviews: Publishes Full Ingredient and Strain Disclosure for Its Three-Strain Probiotic Formula

Delayed-release capsule pairs Bifidobacterium lactis, longum and breve at 9 billion CFUs with xylooligosaccharides and tributyrin; company details capsule technology designed to survive stomach acid and cites general strain research alongside its own label

SAN FRANCISCO, Calif. — September 29, 2026 — Bioma.health has published full ingredient and dosing specifications for Bioma Probiotics, its three-strain probiotic supplement, detailing the formula’s bacterial strains, supporting compounds, capsule delivery technology and the general research landscape associated with each component.

The disclosure comes amid growing scrutiny in the dietary supplement sector, where regulators and consumer advocacy organizations have increasingly called for greater transparency in product labeling. As the global probiotic market continues its rapid expansion, consumers are becoming more discerning about active ingredients, seeking clear evidence and exact strain specifications rather than relying on broad claims or proprietary blends.

Industry analysts point out that full strain-level transparency is becoming a key differentiator in a crowded marketplace. By detailing specific strain identifiers and dosing metrics, companies allow researchers and consumers alike to correlate commercial formulations directly with published clinical literature, marking a notable shift toward higher accountability in wellness supplementation.

“When evaluating multi-strain probiotic supplements, strain transparency is fundamental,” said Dr. Kevin Moore, Product Head at Bioma. “By fully disclosing our specific strains, prebiotic compounds, and target dosages, we empower consumers and health professionals to critically assess the formulation against the broader clinical research landscape.”

Why Strain-Level Disclosure Matters

The probiotic supplement category includes products ranging from single-strain formulas to blends of a dozen or more bacterial species, often disclosed only as a total CFU count without naming individual strains. Bioma’s label identifies each of its three strains by full species name — Bifidobacterium lactis, Bifidobacterium longum and Bifidobacterium breve — a level of specificity the company says is intended to let consumers compare its formula against published strain-level research rather than relying on a generic “probiotic blend” description.

Formula Composition

Each two-capsule daily serving of Bioma delivers 9 billion colony-forming units (CFUs) combined across the three strains; the label does not break out the CFU count per individual strain within that total. The formula also includes 100 milligrams of xylooligosaccharides (XOS), sourced from corn cob powder, and 90 milligrams of tributyrin. Inactive ingredients listed on the label include microcrystalline cellulose, hypromellose, magnesium stearate and silicon dioxide.

Research Context for the Three Strains

Bifidobacterium lactis has been examined in registered clinical research addressing digestive-transit outcomes; one such registered trial examined the HN019 strain of B. lactis in connection with colonic transit time and digestive symptoms.[1] Bioma’s label does not specify which sub-strain designation of B. lactis is used in its formula, so this research should be read as background on the species generally rather than confirmation of an effect specific to Bioma’s strain or CFU count.

Bifidobacterium longum has likewise been studied in combination with other probiotic species in registered research examining immune function and digestive health outcomes, typically in combination with additional strains not present in Bioma’s formula.[2] Bifidobacterium breve has an independent research literature addressing gut microbiota composition, generally conducted using specific proprietary sub-strains and at CFU counts that vary study to study.

The company’s published materials do not cite a clinical trial of the complete three-strain, 9-billion-CFU combination used in Bioma Probiotics specifically. Differences in sub-strain designation, CFU count, delivery format and study population can all affect whether a finding involving one of these species independently transfers to Bioma’s specific formulation — a distinction the guide recommends consumers keep in mind whenever a supplement label names a well-studied bacterial genus without specifying which strain, at what count, was actually tested.

Xylooligosaccharides: A Prebiotic Component

Unlike the probiotic strains, which are live bacteria, xylooligosaccharides function as a prebiotic — a non-digestible fiber compound that serves as a food source for beneficial gut bacteria already present or introduced via supplementation. Bioma’s label lists XOS at 100 milligrams, sourced from corn cob powder rather than a synthetic process. The company positions this ingredient as complementary to the probiotic strains rather than as a bacterial ingredient itself; a prebiotic and a probiotic address different parts of the same general gut-health category, and consumers evaluating the formula should treat them as functioning differently rather than as interchangeable line items on a label.

Tributyrin and the Delayed-Release Capsule

Tributyrin, listed at 90 milligrams, is a compound that breaks down into butyrate, a short-chain fatty acid produced naturally when gut bacteria ferment dietary fiber. The company states that its inclusion is intended to support the gut environment independently of the live bacterial strains, functioning as a third distinct mechanism alongside the probiotic and prebiotic components.

Bioma Probiotics is delivered in a delayed-release vegetarian capsule, a delivery method engineered so the capsule shell resists breakdown in stomach acid and releases its contents further along the digestive tract, closer to where probiotic bacteria are intended to colonize. This is a distinct engineering claim from the ingredient list itself — it addresses whether the bacteria survive transit to the gut, not how many CFUs are in a given serving — and the company’s materials reviewed for this release do not cite independent third-party disintegration testing of this specific capsule.

What the Research Does and Does Not Establish

No clinical trial of the complete Bioma formula — all three strains, the prebiotic, the tributyrin and the delayed-release capsule together — was identified for this release. Each piece of research cited above examined a single strain or compound independently, often using a different sub-strain, CFU count, or delivery method than what appears in Bioma Probiotics. The company’s public materials frame the ingredient list as a compositional disclosure rather than a claim that the combination has been clinically validated as a unit.

Manufacturing and Quality Control

The company states that Bioma is manufactured in an FDA-registered, GMP-certified facility in the United States. As with any dietary supplement manufacturing claim, GMP certification addresses production consistency, ingredient identity and quality-control procedures — it does not constitute FDA approval of the product’s health claims, since dietary supplements are not evaluated by the FDA for effectiveness before sale.

Usage and Safety Information

The labeled serving is two capsules daily, taken with 8 to 12 ounces of water, preferably before breakfast. The company recommends that individuals who are pregnant, nursing, or managing an existing gastrointestinal or immune-related medical condition consult a healthcare professional before beginning use, and that anyone taking prescription medication do the same, since probiotic supplementation can be a relevant factor to disclose during medical care. Consumers with a history of small intestinal bacterial overgrowth or a compromised immune system are advised to seek specific medical guidance before adding any live-bacterial supplement to their routine. Consumers should follow the current physical label for definitive serving instructions and warnings, since online descriptions and packaging can be updated at different times.

Availability and Purchase Terms

Bioma Probiotics is sold directly through the company’s website in one-, three- and six-month package configurations, with per-bottle pricing decreasing at higher quantities and a subscription option available at a further discount. The company advertises a 14-day money-back guarantee, minus shipping costs. Consumers should confirm current pricing, package terms and refund conditions on the official checkout page, since these can change independently of older marketing materials.

Frequently Asked Questions

How many CFUs does Bioma provide per serving? 9 billion CFUs combined across three Bifidobacterium strains, at the labeled two-capsule daily serving; the label does not disclose the per-strain breakdown of that total.

Does the delayed-release capsule guarantee the bacteria reach the gut alive? The capsule is engineered to resist breakdown in stomach acid, but the company’s published materials for this release do not include independent third-party testing confirming survival rates for this specific product.

Is Bioma a treatment for a digestive condition? No. The company markets Bioma as a general dietary supplement and does not represent it as a treatment for any diagnosed gastrointestinal condition.

Does published research on Bifidobacterium prove Bioma works? No. Research cited in this release concerns individual strains, often different sub-strains than the ones in Bioma, studied independently and sometimes in combination with other species not present in this formula.

About Bioma Health

Bioma Health is the parent company of Bioma Probiotics, with operations in San Francisco, California, and Mamavys, Lithuania. The company manufactures Bioma at a facility it identifies as FDA-registered and GMP-certified in the United States.

References

[1] Effect of Bifidobacterium Lactis HN019 on Colonic Transit Time and Digestive Symptoms. ClinicalTrials.gov, NCT01171014.
[2] The Effect of Probiotics (L. Helveticus, B. Longum, and B. Bifidum) on Immune Function and Digestive Health., NCT01709825.

Media Contact

Kevin Moore, Product Head, Bioma health
315 Montgomery Street, San Francisco, CA 94104
Email: hello@bioma.health
Help Center: help.bioma.health

Disclaimer: Bioma Probiotics is a dietary supplement. These statements have not been evaluated by the U.S. Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Research referenced in this release concerns individual strains and compounds studied independently and does not constitute clinical evaluation of the complete Bioma formula. Individual responses to probiotic supplementation may vary. Consult a qualified healthcare professional before use, particularly if pregnant, nursing, managing an existing medical condition, or taking prescription medication.